Combinatorial markers of Mild Cognitive Impairment conversion to Alzheimers Disease - Cytokines and MRI measures together predict disease progression

Journal of Alzheimer's Disease

Volumn 26, Issue SUPPL. 3, 2011, Pages 395-405

  Furney, Simon J ^a   Kronenberg, Deborah ^a   Simmons, Andrew ^a   Güntert, Andreas ^a   Dobson, Richard J ^a   Proitsi, Petroula ^a   Wahlund, Lars Olof ^b   Kloszewska, Iwona ^c   Mecocci, Patrizia ^d   Soininen, Hilkka ^e   Tsolaki, Magda ^f   Vellas, Bruno ^g   Spenger, Christian ^h   Lovestone, Simon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d UNIVERSITY OF PERUGIA   (Italy)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^g Hôpitaux de Toulouse   (France)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimers disease; biomarkers; mild cognitive impairment; MRI; Proteomics

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN E; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; DEATH RECEPTOR 5; EOTAXIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; SCATTER FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNINDEXED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOANALYSIS; BRAIN REGION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EVALUATION; CYTOKINE PRODUCTION; DATA ANALYSIS; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; GENOTYPE; HIGH RISK PATIENT; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

EID: 80055054543     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-0044     Document Type: Article

References (54)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112-2117. (Pubitemid 41797645)
2. Fratiglioni L, Launer LJ, Andersen K, BretelerMM,Copeland JR, Dartigues JF, Lobo A, Martinez-Lage J, Soininen H, Hofman A (2000) Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S10-S15. (Pubitemid 30390599)
3. Pogacic V, Herrling P (2009) List of drugs in development for neurodegenerative diseases. Update June 2008. Neurodegener Dis 6, 37-86.
4. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G,Meguro K, OBrien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimers disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746. (Pubitemid 47058377)
5. Modrego PJ (2006) Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res 3, 161-170.
6. Mitchell AJ, Shiri-Feshki M (2009) Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 119, 252-265.
7. Bruscoli M, Lovestone S (2004) Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 16, 129-140. (Pubitemid 38963102)
8. Diniz SO, Pinto JA, Forlenza OV (2008) Do CSF total tau, phosphorylated tau, and-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimers disease? A systematic review and meta-analysis of the literature. World Journal of Biological Psychiatry 9, 172-182.
9. Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ (2010) Prediction of MCI to AD conversion via MRI CSF biomarkers and pattern classification. Neurobiol Aging.
10. Desikan RS, Cabral HJ, Fischl B, Guttmann CR, Blacker D, Hyman BT, Albert MS, Killiany RJ (2009) Temporoparietal MR imaging measures of atrophy in subjects with mild cognitive impairment that predict subsequent diagnosis of Alzheimer disease. AJNR Am J Neuroradiol 30, 532-538.
11. Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ (2007) Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 68, 828-836. (Pubitemid 46568534)
12. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR, Jr., Aisen PS, Thal LJ (2008) Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology 70, 191-199.
13. Jack CR, Jr, Petersen RC, Xu YC, OBrien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52, 1397-1403. (Pubitemid 29190530)
14. Liu Y, Paajanen T, Zhang Y, Westman E, Wahlund LO, Simmons A, Tunnard C, Sobow T, Mecocci P, Tsolaki M, Vellas B, Muehlboeck S, Evans A, Spenger C, Lovestone S, Soininen H (2010) Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimers disease. Neurobiol Aging 31, 1375-1385.
15. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R,Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73, 754-760.
16. Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimers disease. NeuroRx 1, 213-225. (Pubitemid 46589353)
17. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimers disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
18. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR, Jr, Weiner MW, Jagust WJ (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology.
19. Cuingnet R, Gerardin E, Tessieras J, Auzias G, Lehericy S, Habert MO, Chupin M, Benali H, Colliot O (2010) Automatic classification of patients with Alzheimers disease from structural MRI:Acomparison of ten methods using the ADNI database. Neuroimage.
20. Akuffo EL, Davis JB, Fox SM, Gloger IS, Hosford D, Kinsey EE, Jones NA, Nock CM, Roses AD, Saunders AM, Skehel JM, Smith MA, Cutler P (2008) The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimers disease patients responding to treatment with rosiglitazone. Biomarkers 13, 618-636.
21. Thambisetty M, Simmons A,Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Guntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, OBrien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67, 739-748.
22. Thambisetty M, Hye A, Foy C, Daly E, Glover A, Cooper A, Simmons A, Murphy D, Lovestone S (2008) Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimers disease. J Neurol 255, 1712-1720.
23. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimers diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362. (Pubitemid 350073592)
24. OBryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R (2010) A Serum Protein-Based Algorithm for the Detection of Alzheimer Disease. Arch Neurol 67, 1077-1081.
25. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A (2004) MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63, 2332-2340. (Pubitemid 40024346)
26. Borroni B, Premi E, Di Luca M, PadovaniA(2007) Combined biomarkers for early Alzheimer disease diagnosis. Curr Med Chem 14, 1171-1178. (Pubitemid 46739318)
27. Visser PJ, Scheltens P, Verhey FR, Schmand B, Launer LJ, Jolles J, Jonker C (1999) Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol 246, 477-485. (Pubitemid 29326844)
28. Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, Seki T, Hirai H, Chiba H, Itoh M, Sasaki H (2002) Combined analysis of CSF tau levels and (123)Iiodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimers disease. Am J Psychiatry 159, 474-476. (Pubitemid 34184746)
29. Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, de Leon MJ, Doty RL, Stern Y, Pelton GH (2008) Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimers disease. Biol Psychiatry 64, 871-879.
30. Ewers M,Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR, Jr., Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H Prediction of conversion from mild cognitive impairment to Alzheimers disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging.
31. Lovestone S, Francis P, Strandgaard K (2007) Biomarkers for disease modification trials-the innovative medicines initiative and AddNeuroMed. J Nutr Health Aging 11, 359-361. (Pubitemid 47121941)
32. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteome-based plasma biomarkers for Alzheimers disease. Brain 129, 3042-3050. (Pubitemid 44684524)
33. Jack CR, Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, Ward JLW, Dale C, Felmlee AM, Gunter JP, Hill JL, Killiany DL, Schuff R, Fox-Bosetti N, Lin S, Studholme C, DeCarli C, Krueger CS, Ward G, Metzger HA, Scott GJ, Mallozzi KT, Blezek R, Levy D, Debbins J, Fleisher JP, Albert AS, Green M, Bartzokis R, Glover G, Mugler G, Weiner J, MW (2008) The Alzheimers Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 27, 685-691. (Pubitemid 351508080)
34. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Wahlund LO, Soininen H, Lovestone S, Evans A, Spenger C (2009) MRI measures of Alzheimers disease and the AddNeuroMed study. Ann N Y Acad Sci 1180, 47-55.
35. Simmons A, Other AN, Other AN, Lovestone S(in press) The AddNeuroMed framework for multi-centre MRI assessment of longitudinal changes in Alzheimers disease : experience from the first 24 months. Int J Ger Psych.
36. Fischl B, Dale AM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 97, 11050-11055.
37. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM (2002) Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341-355. (Pubitemid 34162530)
38. Fischl B, Salat DH, van der Kouwe AJ, Makris N, Segonne F, Quinn BT, Dale AM (2004) Sequence-independent segmentation of magnetic resonance images. Neuroimage 23(1), S69-S84. (Pubitemid 39429376)
39. Frank E, Hall M, Trigg L, Holmes G, Witten IH (2004) Data mining in bioinformatics using Weka. Bioinformatics 20, 2479-2481. (Pubitemid 39429925)
40. Ben-Hur A, Ong CS, Sonnenburg S, Scholkopf B, Ratsch G (2008) Support vector machines and kernels for computational biology. PLoS Comput Biol 4, e1000173.
41. den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler MM (2006) Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry 63, 57-62. (Pubitemid 43037469)
42. Alvarez XA, Franco A, Fernandez-Novoa L, Cacabelos R (1996) Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol 29, 237-252. (Pubitemid 27016932)
43. De Luigi A, Fragiacomo C, Lucca U, Quadri P, Tettamanti M, Grazia De Simoni M (2001) Inflammatory markers in Alzheimers disease and multi-infarct dementia. Mech Ageing Dev 122, 1985-1995. (Pubitemid 32925108)
44. Lombardi VR, Garcia M, Rey L, Cacabelos R (1999) Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimers Disease (AD) individuals. J Neuroimmunol 97, 163-171. (Pubitemid 29301426)
45. Beloosesky Y, Salman H, Bergman M, Bessler H, Djaldetti M (2002) Cytokine levels and phagocytic activity in patients with Alzheimers disease. Gerontology 48, 128-132. (Pubitemid 34310066)
46. Di Bona D, Plaia A,Vasto S, Cavallone L, Lescai F, Franceschi C, Licastro F, Colonna-Romano G, Lio D, Candore G, Caruso C (2008) Association between the interleukin-1beta polymorphisms and Alzheimers disease: a systematic review and meta-analysis. Brain Res Rev 59, 155-163.
47. Yasutake C, Kuroda K, Yanagawa T, Okamura T, Yoneda H (2006) Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimers disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 256, 402-406. (Pubitemid 44584054)
48. Mrak RE, GriffinWS(2005) Potential inflammatory biomarkers in Alzheimers disease. J Alzheimers Dis 8, 369-375.
49. Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, Chae CB (2004) Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimers disease. Neurobiol Aging 25, 283-290. (Pubitemid 38220962)
50. Chiappelli M, Borroni B, Archetti S, Calabrese E, Corsi MM, Franceschi M, Padovani A, Licastro F (2006) VEGF gene and phenotype relation with Alzheimers disease and mild cognitive impairment. Rejuvenation Res 9, 485-493. (Pubitemid 46100670)
51. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, Kumar P (2002) Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimers disease and vascular dementia. Neurobiol Aging 23, 237-243. (Pubitemid 34137098)
52. Mateo I, Llorca J, Infante J, Rodriguez-Rodriguez E, Fernandez-Viadero C, Pena N, Berciano J, Combarros O (2007) Low serum VEGF levels are associated with Alzheimers disease. Acta Neurol Scand 116, 56-58. (Pubitemid 46976267)
53. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Marksteiner J, Humpel C (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimers disease and other dementias. Dement Geriatr Cogn Disord 21, 9-15. (Pubitemid 41797965)
54. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M (2009) Rapid progression from mild cognitive impairment to Alzheimers disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord 27, 458-464.